Transgenic Plants as Low-Cost Platform for Chemotherapeutic Drugs Screening
AbstractIn this work we explored the possibility of using genetically modified Arabidopsis thaliana plants as a rapid and low-cost screening tool for evaluating human anticancer drugs action and efficacy. Here, four different inhibitors with a validated anticancer effect in humans and distinct mechanism of action were screened in the plant model for their ability to interfere with the cytoskeletal and endomembrane networks. We used plants expressing a green fluorescent protein (GFP) tagged microtubule-protein (TUA6-GFP), and three soluble GFPs differently sorted to reside in the endoplasmic reticulum (GFPKDEL) or to accumulate in the vacuole through a COPII dependent (AleuGFP) or independent (GFPChi) mechanism. Our results demonstrated that drugs tested alone or in combination differentially influenced the monitored cellular processes including cytoskeletal organization and endomembrane trafficking. In conclusion, we demonstrated that A. thaliana plants are sensitive to the action of human chemotherapeutics and can be used for preliminary screening of drugs efficacy. The cost-effective subcellular imaging in plant cell may contribute to better clarify drugs subcellular targets and their anticancer effects. View Full-Text
Share & Cite This Article
Vergara, D.; de Domenico, S.; Maffia, M.; Piro, G.; Sansebastiano, G.-P.D. Transgenic Plants as Low-Cost Platform for Chemotherapeutic Drugs Screening. Int. J. Mol. Sci. 2015, 16, 2174-2186.
Vergara D, de Domenico S, Maffia M, Piro G, Sansebastiano G-PD. Transgenic Plants as Low-Cost Platform for Chemotherapeutic Drugs Screening. International Journal of Molecular Sciences. 2015; 16(1):2174-2186.Chicago/Turabian Style
Vergara, Daniele; de Domenico, Stefania; Maffia, Michele; Piro, Gabriella; Sansebastiano, Gian-Pietro D. 2015. "Transgenic Plants as Low-Cost Platform for Chemotherapeutic Drugs Screening." Int. J. Mol. Sci. 16, no. 1: 2174-2186.